Publications by authors named "M V Schaverien"
Background: Two-stage prosthetic breast reconstruction involves the exchange of tissue expanders for implants, but complications of this procedure can necessitate revision surgeries and implant removal. The choice between remote incision (RI) and traditional access via existing mastectomy scars (MS) for this exchange remains underexplored. RIs offer potential benefits by placing the incision at a region of higher quality tissue, prompting our comparative analysis of complications between RI and MS.
View Article and Find Full Text PDFImportance: Premastectomy radiotherapy (PreMRT) is a new treatment sequence to avoid the adverse effects of radiotherapy on the final breast reconstruction while achieving the benefits of immediate breast reconstruction (IMBR).
Objective: To evaluate outcomes among patients who received PreMRT and regional nodal irradiation (RNI) followed by mastectomy and IMBR.
Design, Setting, And Participants: This was a phase 2 single-center randomized clinical trial conducted between August 3, 2018, and August 2, 2022, evaluating the feasibility and safety of PreMRT and RNI (including internal mammary lymph nodes).
Purpose: For breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome measures (OMs) are recommended to be used to measure standardized outcome domains to fully assess the burden of the disease and efficacy of interventions? An integral component of a standardized core outcome set (COS) are the OMs used to measure the COS.
Methods: A supplemental online survey was linked to a Delphi study investigating a COS for BCRL. OMs were limited to a maximum of 10 options for each outcome domain (OD).
Article Synopsis
- The study aims to identify key outcome domains for breast cancer survivors experiencing breast cancer-related lymphedema (BCRL) to standardize how the disease's burden and treatment effectiveness are measured.
- A group of BCRL experts utilized Delphi methodology, completing two online surveys to reach a consensus on important outcome domains, with 12 being ultimately included in the Core Outcome Set (COS).
- The COS provides a comprehensive framework to consistently evaluate BCRL, potentially improving clinical practice and research by minimizing variations in outcomes reported by different healthcare disciplines.
Article Synopsis
- - Pembrolizumab added to neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) has led to higher rates of pathologic complete responses (pCRs) compared to traditional treatments.
- - In a study of 87 patients, 67.8% achieved overall pCR, while 24.1% experienced surgical complications related to the treatment, including changes to their surgical plans.
- - The findings suggest that using pembrolizumab in NAC offers significant cancer control benefits but also presents important considerations for surgical management and potential complications.